-
Unlike other monoclonal antibody therapies, Evusheld is not meant to treat active coronavirus infection. Instead, it's preventative medicine for people with compromised immune systems.
-
Haiti's COVID-19 case and death counts remain relatively low but much of that count has increased in the past month and the country has yet to receive vaccines.
-
Oxford-AstraZeneca promised its COVID-19 vaccine would be effective, cheap and available worldwide. Five months after its launch, the path forward has been anything but smooth.
-
The administration has faced growing calls to send its stockpile of the AstraZeneca vaccine, which is not yet cleared for use in the U.S., to help countries hit hard by the virus.
-
Updated study results say the vaccine is 76% effective against symptomatic COVID-19 and 100% effective against severe disease. Independent monitors had been concerned about a previous report.
-
In an unusual post-midnight statement, the National Institute of Allergy and Infectious Diseases said AstraZeneca might have used old data for its COVID-19 vaccine trial.
-
Results of the trial, which involved more than 32,000 volunteers, showed two doses of the vaccine administered four weeks apart had an efficacy of 79% at preventing symptoms of COVID-19.
-
Several other countries including France, Germany, the Netherlands and Ireland moved to suspend injections of the vaccine this week.
-
European Commission President Ursula von der Leyen announced Sunday that AstraZeneca would also deliver the vaccines one week earlier than originally scheduled.
-
The British government has ordered 100 million doses, enough to vaccinate 50 million residents.